摘要

Accumulation of alpha-synuclein (alpha-syn) leading to the formation of insoluble intracellular aggregates named Lewy bodies is proposed to have a significant role in Parkinson's disease (PD) pathology. Nonhuman primate (NHP) models of PD have proven essential for understanding the neurobiological basis of the disease and for the preclinical evaluation of first-in-class and invasive therapies. In addition to neurotoxin, aging and intracerebral gene transfer models, a new generation of models using inoculations of alpha-syn formulations, as well as transgenic methods is emerging. Understanding of their advantages and limitations will be essential when choosing a platform to evaluate a-syn-related pathology and interpreting the test results of new treatments targeting alpha-syn aggregation. In this review we aim to provide insight on this issue by critically analyzing the differences in endogenous alpha-syn, as well as alpha-syn pathology in PD and PD NHP models.

  • 出版日期2015-11-30

全文